Advantages of a next generation sequencing targeted approach for the molecular diagnosis of retinoblastoma

BMC Cancer

Table 2 Coverage level through the target region for patient ID 24 (library preparation performed with Panel B)

Exon	Amplicon start	Amplicon end	Coverage	Exon	Amplicon start	Amplicon end	Coverage
5’UTR+1	48877740	48878189	320	17	48955328	48955770	970
	48878120	48878544	499	18	49027054	49027468	1800
2	48881319	48881718	750	19	49030255	49030669	635
3	48916666	48917104	1500	20	49033602	49034002	2300
4	48919157	48919573	840		49033928	49034359	3000
5	48921888	48922320	1100	21	49037776	49038175	349
6	48923035	4982348	450	22	49038987	49039397	1300
7	48934082	48934522	2100	23	49039325	49039761	600
8	48936850	18937296	800	24	49047419	49047829	300
9	48938842	48939254	3150	25	49050772	49051184	2900
10	48971551	48941965	3692	26	49051422	49051822	296
11	48942426	48942874	65	27	49053981	49054380	5000
	48972798	48943224	135	3’UTR	49054269	49054693	1957
12	48947438	48947854	1371	3’UTR	49051617	49055024	2607
13	48950985	48951409	1500	3’UTR	49054949	49055395	1321
14	48953395	48953828	659	3’UTR	49055319	49055740	2847
	48953757	48954206	456	3’UTR	49055661	49056085	428
15-16	48954127	48954562	431	3’UTR	49056009	49056429	2458

ISSN: 1471-2407